Leo Cancer Care is thrilled to announce the successful raise of $25,300,000 in our latest funding round, marking a pivotal moment in our mission to revolutionize Radiation Therapy delivery and accessibility. Founded on over a century of combined radiation therapy experience, our innovative company is dedicated to challenging the status quo by focusing on two transformative goals: enhancing the quality of radiation therapy through upright patient positioning and broadening patient access through the removal of cumbersome gantries. With its roots in Australia and global research underpinning its clinical benefits, Leo Cancer Care is poised to change the face of cancer treatment by shifting the focus from rotating bulky machines to rotating the patient—a change that could redefine treatment protocols worldwide.
These funds will accelerate our journey towards FDA approval and CE marking, ensuring our state-of-the-art family of products is poised to enter the market with the highest standards of safety and efficiency. Our vision is clear: to streamline and improve the patient treatment experience by making it more comfortable, efficient, and personalized, ultimately offering hope and renewed control in what can be a challenging process. This investment represents not only a vote of confidence in our pioneering technology and dedicated team but also an essential step towards making life-saving radiation therapy available to more patients in more places around the globe. As we move forward, this funding will drive high-priority initiatives, including advanced clinical trials and expanded regulatory reviews, all in the service of improving patient care and delivering a better, more accessible radiation treatment experience.
